New Real-World Data Presented at OPTIONS XI Show Cell-Based and MF59®-Adjuvanted Influenza Vaccines Can Reduce the Burden of Seasonal Influenza on Hospitals and Health Systems
SUMMIT, N.J., Sept. 26, 2022 /PRNewswire/ -- CSL Seqirus, a business of CSL Limited (ASX:CSL), today announced new data from four real-world studi...
Source: businessinsider.com